{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["BPH", "HBX-5", "RWPE-1", "WPMY-1", "inflammation", "proliferation", "testosterone-induced BPH rat model"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30322186", "DateCompleted": {"Year": "2018", "Month": "12", "Day": "18"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "10", "Day": "14"}], "Language": ["eng"], "ELocationID": ["2638", "10.3390/molecules23102638"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "23", "Issue": "10", "PubDate": {"Year": "2018", "Month": "Oct", "Day": "14"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia.", "Abstract": {"AbstractText": ["Benign prostatic hyperplasia (BPH), an age-dependent disorder with a prevalence percentage of 60% in the 60s, has been found to involve an androgenic hormone imbalance that causes confusion between cell apoptosis and proliferation. Because general medications for BPH treatment have undesirable side effects, the development of effective alternative medicines has been considered. HBX-5 is a newly developed formula with the aim of improving BPH, and is composed of nine medicinal herbs. BPH was induced in the rats by intramuscular injection of testosterone propionate after castration. Rats were divided into six groups, and the efficacy of HBX-5 on testosterone-induced BPH in rats was estimated. In addition, RWPE-1 and WPMY-1 cells were used to demonstrate the effect of HBX-5 on BPH in vitro model. Compared with the control group, HBX-5 administration group suppressed BPH manifestations, such as excessive development of prostate, and increase of serum dihydrotestosterone and 5\u03b1-reductase concentrations. Furthermore, immunohistochemistry analysis revealed that HBX-5 significantly decreased the expression of androgen receptor (AR) and proliferating cell nuclear antigen (PCNA). In addition, results of RWPE-1 and WPMY-1 cells showed that HBX-5 inhibited the over-expression of AR and PSA in DHT-induced prostate hyperplastic microenvironments."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do 26339, Korea. wlsqh92@gmail.com."}], "LastName": "Jin", "ForeName": "Bo-Ram", "Initials": "BR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do 26339, Korea. hyojung_95@naver.com."}], "LastName": "Kim", "ForeName": "Hyo-Jung", "Initials": "HJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Meridian & Acupoint, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do 26339, Korea. psk7509@sangji.ac.kr."}], "LastName": "Park", "ForeName": "Sang-Kyun", "Initials": "SK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Research Institue of Hawon Pharmaceutical, Jangheung 59338, Korea. mskim1210@naver.com."}], "LastName": "Kim", "ForeName": "Myoung-Seok", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Research Institue of Hawon Pharmaceutical, Jangheung 59338, Korea. gusins@hanmail.net."}], "LastName": "Lee", "ForeName": "Kwang-Ho", "Initials": "KH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Research Institue of Hawon Pharmaceutical, Jangheung 59338, Korea. polorman@naver.com."}], "LastName": "Yoon", "ForeName": "Il-Joo", "Initials": "IJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do 26339, Korea. hjan@sj.ac.kr."}], "LastName": "An", "ForeName": "Hyo-Jin", "Initials": "HJ"}], "GrantList": [{"GrantID": "HI16C0477", "Agency": "Korea Health Industry Development Institute", "Country": "Republic of Korea"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Proliferating Cell Nuclear Antigen"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Androgen"}, {"RegistryNumber": "08J2K08A3Y", "NameOfSubstance": "Dihydrotestosterone"}, {"RegistryNumber": "EC 1.3.99.5", "NameOfSubstance": "3-Oxo-5-alpha-Steroid 4-Dehydrogenase"}, {"RegistryNumber": "WI93Z9138A", "NameOfSubstance": "Testosterone Propionate"}], "MeshHeadingList": [{"QualifierName": ["blood"], "DescriptorName": "3-Oxo-5-alpha-Steroid 4-Dehydrogenase"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["blood"], "DescriptorName": "Dihydrotestosterone"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Disease Progression"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Injections, Intramuscular"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proliferating Cell Nuclear Antigen"}, {"QualifierName": ["blood", "chemically induced", "drug therapy"], "DescriptorName": "Prostatic Hyperplasia"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, Androgen"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Testosterone Propionate"}], "CoiStatement": "The authors declare no competing financial interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Roehrborn C.G. Benign prostatic hyperplasia: An overview. Rev. Urol. 2005;7:S3\u2013S14.", "ArticleIdList": ["PMC1477638", "16985902"]}, {"Citation": "Briganti A., Capitanio U., Suardi N., Gallina A., Salonia A., Bianchi M., Tutolo M., Di Girolamo V., Guazzoni G., Rigatti P., et al. Benign prostatic hyperplasia and its aetiologies. Eur. Urol. Suppl. 2009;8:865\u2013871. doi: 10.1016/j.eursup.2009.11.002.", "ArticleIdList": ["10.1016/j.eursup.2009.11.002"]}, {"Citation": "Gandaglia G., Briganti A., Gontero P., Mondaini N., Novara G., Salonia A., Sciarra A., Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (bph) BJU Int. 2013;112:432\u2013441. doi: 10.1111/bju.12118.", "ArticleIdList": ["10.1111/bju.12118", "23650937"]}, {"Citation": "Delongchamps N.B., de la Roza G., Chandan V., Jones R., Sunheimer R., Threatte G., Jumbelic M., Haas G.P. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J. Urol. 2008;179:1736\u20131740. doi: 10.1016/j.juro.2008.01.034.", "ArticleIdList": ["10.1016/j.juro.2008.01.034", "PMC2661538", "18343414"]}, {"Citation": "Zhang X., Zhang Q., Zhang Z., Na Y., Guo Y. Apoptosis profiles in benign prostatic hyperplasia: Close associations of cell kinetics with percent area density of histologic composition. Urology. 2006;68:905\u2013910. doi: 10.1016/j.urology.2006.05.013.", "ArticleIdList": ["10.1016/j.urology.2006.05.013", "17070390"]}, {"Citation": "Lepor H., Kazzazi A., Djavan B. Alpha-blockers for benign prostatic hyperplasia: The new era. Curr. Opin. Urol. 2012;22:7\u201315. doi: 10.1097/MOU.0b013e32834d9bfd.", "ArticleIdList": ["10.1097/MOU.0b013e32834d9bfd", "22080875"]}, {"Citation": "Lepor H. Medical treatment of benign prostatic hyperplasia. Rev. Urol. 2011;13:20\u201333.", "ArticleIdList": ["PMC3151584", "21826125"]}, {"Citation": "Shi H., Zhou C., Li Y., Wang G., Sun Y. Anti-inflammatory effect of aconitines. China J. Chin. Mater. Med. 1990;15:174\u2013177, 192.", "ArticleIdList": ["2150749"]}, {"Citation": "Kang D.G., Choi D.H., Lee J.K., Lee Y.J., Moon M.K., Yang S.N., Kwon T.O., Kwon J.W., Kim J.S., Lee H.S. Endothelial no/cgmp-dependent vascular relaxation of cornuside isolated from the fruit of cornus officinalis. Planta. Med. 2007;73:1436\u20131440. doi: 10.1055/s-2007-990243.", "ArticleIdList": ["10.1055/s-2007-990243", "17926269"]}, {"Citation": "Jeon H.J., Chung K.S., An H.J. Anti-proliferation effects of cistanches salsa on the progression of benign prostatic hyperplasia. Can. J. Physiol. Pharmacol. 2016;94:104\u2013111. doi: 10.1139/cjpp-2015-0112.", "ArticleIdList": ["10.1139/cjpp-2015-0112", "27123496"]}, {"Citation": "Yang W.M., Chang M.S., Park S.K. Effects of psoralea corylifolia on the camp-responsive element modulator (crem) expression and spermatogenesis in rats. J. Ethnopharmacol. 2008;117:503\u2013506. doi: 10.1016/j.jep.2008.02.016.", "ArticleIdList": ["10.1016/j.jep.2008.02.016", "18374528"]}, {"Citation": "Zhao W., Ye Q., Tan X., Jiang H., Li X., Chen K., Kinghorn A.D. Three new sesquiterpene glycosides from dendrobium nobile with immunomodulatory activity. J. Nat. Prod. 2001;64:1196\u20131200. doi: 10.1021/np0102612.", "ArticleIdList": ["10.1021/np0102612", "11575955"]}, {"Citation": "Peng S.J., Lu R.K., Yu L.H. Effects of semen cuscutae, rhizoma curculiginis, radix morindae officinalis on human spermatozoan\u2019s motility and membrane function in vitro. Chin. J. Integr. Tradit. West. Med. 1997;17:145\u2013147.", "ArticleIdList": ["9863078"]}, {"Citation": "Yen F.L., Wu T.H., Lin L.T., Lin C.C. Hepatoprotective and antioxidant effects of cuscuta chinensis against acetaminophen-induced hepatotoxicity in rats. J. Ethnopharmacol. 2007;111:123\u2013128. doi: 10.1016/j.jep.2006.11.003.", "ArticleIdList": ["10.1016/j.jep.2006.11.003", "17145147"]}, {"Citation": "Yadav U.C., Baquer N.Z. Pharmacological effects of trigonella foenum-graecum l. In health and disease. Pharm. Biol. 2014;52:243\u2013254. doi: 10.3109/13880209.2013.826247.", "ArticleIdList": ["10.3109/13880209.2013.826247", "24102093"]}, {"Citation": "Li J., Tian Y., Guo S., Gu H., Yuan Q., Xie X. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS ONE. 2018;13:e0191469. doi: 10.1371/journal.pone.0191469.", "ArticleIdList": ["10.1371/journal.pone.0191469", "PMC5774778", "29351556"]}, {"Citation": "Mosli H.H., Esmat A., Atawia R.T., Shoieb S.M., Mosli H.A., Abdel-Naim A.B. Metformin attenuates testosterone-induced prostatic hyperplasia in rats: A pharmacological perspective. Sci. Rep. 2015;5:15639. doi: 10.1038/srep15639.", "ArticleIdList": ["10.1038/srep15639", "PMC4616049", "26492952"]}, {"Citation": "Izumi K., Mizokami A., Lin W.J., Lai K.P., Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am. J. Pathol. 2013;182:1942\u20131949. doi: 10.1016/j.ajpath.2013.02.028.", "ArticleIdList": ["10.1016/j.ajpath.2013.02.028", "PMC3668026", "23570837"]}, {"Citation": "Steers W.D. 5\u03b1-reductase activity in the prostate. Urology. 2001;58:17\u201324. doi: 10.1016/S0090-4295(01)01299-7.", "ArticleIdList": ["10.1016/S0090-4295(01)01299-7", "11750244"]}, {"Citation": "Kyprianou N., Tu H., Jacobs S.C. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Pathol. 1996;27:668\u2013675. doi: 10.1016/S0046-8177(96)90396-2.", "ArticleIdList": ["10.1016/S0046-8177(96)90396-2", "8698310"]}, {"Citation": "Wang X., Lin W.J., Izumi K., Jiang Q., Lai K.P., Xu D., Fang L.Y., Lu T., Li L., Xia S., et al. Increased infiltrated macrophages in benign prostatic hyperplasia (bph): Role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J. Biol. Chem. 2012;287:18376\u201318385. doi: 10.1074/jbc.M112.355164.", "ArticleIdList": ["10.1074/jbc.M112.355164", "PMC3365773", "22474290"]}, {"Citation": "Rick F.G., Schally A.V., Block N.L., Nadji M., Szepeshazi K., Zarandi M., Vidaurre I., Perez R., Halmos G., Szalontay L. Antagonists of growth hormone-releasing hormone (ghrh) reduce prostate size in experimental benign prostatic hyperplasia. Proc. Natl. Acad. Sci. USA. 2011;108:3755\u20133760. doi: 10.1073/pnas.1018086108.", "ArticleIdList": ["10.1073/pnas.1018086108", "PMC3048153", "21321192"]}, {"Citation": "Vela-Navarrete R., Escribano-Burgos M., Farre A.L., Garcia-Cardoso J., Manzarbeitia F., Carrasco C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J. Urol. 2005;173:507\u2013510. doi: 10.1097/01.ju.0000150533.94952.25.", "ArticleIdList": ["10.1097/01.ju.0000150533.94952.25", "15643230"]}, {"Citation": "Lilja H. Biology of prostate-specific antigen. Urology. 2003;62:27\u201333. doi: 10.1016/S0090-4295(03)00775-1.", "ArticleIdList": ["10.1016/S0090-4295(03)00775-1", "14607215"]}, {"Citation": "Siiteri P.K., Wilson J.D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J. Clin. Investig. 1970;49:1737\u20131745. doi: 10.1172/JCI106391.", "ArticleIdList": ["10.1172/JCI106391", "PMC322657", "4194768"]}, {"Citation": "Kato T., Ishibe T., Hirayama M., Fukushige M., Takenaka I., Kazuta M. Basic studies on the prostate of rat under various hormonal environment. Endocrinol. Jpn. 1965;12:1\u20138. doi: 10.1507/endocrj1954.12.1.", "ArticleIdList": ["10.1507/endocrj1954.12.1", "14331291"]}, {"Citation": "Pandita R.K., Persson K., Hedlund P., Andersson K.E. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate. 1998;35:102\u2013108. doi: 10.1002/(SICI)1097-0045(19980501)35:2<102::AID-PROS3>3.0.CO;2-L.", "ArticleIdList": ["10.1002/(SICI)1097-0045(19980501)35:2<102::AID-PROS3>3.0.CO;2-L", "9568673"]}, {"Citation": "Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev. Urol. 2004;6:S3\u2013S10.", "ArticleIdList": ["PMC1472917", "16985922"]}, {"Citation": "Wu X., Gu Y., Li L. The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of qing ye dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicol. Lett. 2017;265:9\u201316. doi: 10.1016/j.toxlet.2016.11.011.", "ArticleIdList": ["10.1016/j.toxlet.2016.11.011", "27866977"]}, {"Citation": "Uygur M.C., Gur E., Arik A.I., Altug U., Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study. Andrologia. 1998;30:5\u201310. doi: 10.1111/j.1439-0272.1998.tb01375.x.", "ArticleIdList": ["10.1111/j.1439-0272.1998.tb01375.x", "9567164"]}, {"Citation": "Bauman T.M., Nicholson T.M., Abler L.L., Eliceiri K.W., Huang W., Vezina C.M., Ricke W.A. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS ONE. 2014;9:e109102. doi: 10.1371/journal.pone.0109102.", "ArticleIdList": ["10.1371/journal.pone.0109102", "PMC4183548", "25275645"]}, {"Citation": "Minutoli L., Rinaldi M., Marini H., Irrera N., Crea G., Lorenzini C., Puzzolo D., Valenti A., Pisani A., Adamo E.B., et al. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia. Int. J. Mol. Sci. 2016;17:8. doi: 10.3390/ijms17081311.", "ArticleIdList": ["10.3390/ijms17081311", "PMC5000708", "27529214"]}, {"Citation": "Kim T.H., Lim H.J., Kim M.S., Lee M.S. Dietary supplements for benign prostatic hyperplasia: An overview of systematic reviews. Maturitas. 2012;73:180\u2013185. doi: 10.1016/j.maturitas.2012.07.007.", "ArticleIdList": ["10.1016/j.maturitas.2012.07.007", "22883375"]}, {"Citation": "Calixto J.B. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents) Braz. J. Med. Biol. Res. 2000;33:179\u2013189. doi: 10.1590/S0100-879X2000000200004.", "ArticleIdList": ["10.1590/S0100-879X2000000200004", "10657057"]}, {"Citation": "Fibbi B., Penna G., Morelli A., Adorini L., Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 2010;33:475\u2013488. doi: 10.1111/j.1365-2605.2009.00972.x.", "ArticleIdList": ["10.1111/j.1365-2605.2009.00972.x", "19508330"]}, {"Citation": "Iacopino F., Angelucci C., Lama G., Zelano G., La Torre G., D\u2019Addessi A., Giovannini C., Bertaccini A., Macaluso M.P., Martorana G., et al. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. Anticancer Res. 2006;26:1849\u20131854.", "ArticleIdList": ["16827116"]}, {"Citation": "Tanguay S., Awde M., Brock G., Casey R., Kozak J., Lee J., Nickel J.C., Saad F. Diagnosis and management of benign prostatic hyperplasia in primary care. Can. Urol. Assoc. J. 2009;3:S92\u2013S100. doi: 10.5489/cuaj.1116.", "ArticleIdList": ["10.5489/cuaj.1116", "PMC2698785", "19543429"]}, {"Citation": "Wu Z.L., Yuan Y., Geng H., Xia S.J. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian. J. Androl. 2012;14:316\u2013319. doi: 10.1038/aja.2011.154.", "ArticleIdList": ["10.1038/aja.2011.154", "PMC3735085", "22157983"]}, {"Citation": "Wang W., Bergh A., Damber J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61:60\u201372. doi: 10.1002/pros.20061.", "ArticleIdList": ["10.1002/pros.20061", "15287094"]}, {"Citation": "Novara G., Galfano A., Berto R.B., Ficarra V., Navarrete R.V., Artibani W. Inflammation, apoptosis, and bph: What is the evidence? Eur. Urol. Suppl. 2006;5:401\u2013409. doi: 10.1016/j.eursup.2006.02.003.", "ArticleIdList": ["10.1016/j.eursup.2006.02.003"]}, {"Citation": "Banerjee P.P., Banerjee S., Brown T.R. Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes. Endocrinology. 2002;143:1825\u20131832. doi: 10.1210/endo.143.5.8763.", "ArticleIdList": ["10.1210/endo.143.5.8763", "11956165"]}, {"Citation": "Hendriksen P.J., Dits N.F., Kokame K., Veldhoven A., van Weerden W.M., Bangma C.H., Trapman J., Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006;66:5012\u20135020. doi: 10.1158/0008-5472.CAN-05-3082.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-3082", "16707422"]}, {"Citation": "Zhong W., Peng J., He H., Wu D., Han Z., Bi X., Dai Q. Ki-67 and pcna expression in prostate cancer and benign prostatic hyperplasia. Clin. Invest Med. 2008;31:E8\u2013E15. doi: 10.25011/cim.v31i1.3136.", "ArticleIdList": ["10.25011/cim.v31i1.3136", "18312749"]}]}], "History": [{"Year": "2018", "Month": "9", "Day": "5"}, {"Year": "2018", "Month": "10", "Day": "8"}, {"Year": "2018", "Month": "10", "Day": "13"}, {"Year": "2018", "Month": "10", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "12", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "14"}], "PublicationStatus": "epublish", "ArticleIdList": ["30322186", "PMC6222778", "10.3390/molecules23102638", "molecules23102638"]}}]}